RELATED STUDY

The pharmacological case for cannabigerol (CBG)

Key Findings:  CBG interacts with alpha-2 adrenoceptors and 5-HT1A. Data suggests that CBG may have therapeutic potential in treating neurological disorders such as Huntington's Disease, Parkinson's Disease, and MS for example. In addition, it may also induce antibacterial activity and produce beneficial effects in cases of inflammatory bowel disease.